Metoclopramide and QTc Prolongation

Evidence of QTc Prolongation

Metoclopramide is specifically listed as an antiemetic that increases the risk of QT prolongation in clinical guidelines, according to the European Respiratory Society, as published in Thorax 1

Concomitant use with other QT-prolonging medications significantly increases risk, as stated by the European Society of Cardiology 1, 2
Electrolyte abnormalities, particularly hypokalemia, hypomagnesemia, or hypocalcemia, increase the risk of QTc prolongation, as reported by the American Heart Association 2, 3
Older age and female sex are risk factors for QTc prolongation, according to the European Society of Cardiology 2
Underlying heart disease, especially left ventricular hypertrophy, ischemia, or low ejection fraction, increases the risk of QTc prolongation, as stated by the American Heart Association 3
Slow heart rate or bradyarrhythmias increase the risk of QTc prolongation, as reported by the American Heart Association 3
Genetic predisposition to QT prolongation is a risk factor, according to the American Heart Association 3

Obtain baseline ECG before initiating treatment with metoclopramide if the patient has other risk factors for QT prolongation, as recommended by the American Heart Association 3, 4
Document QTc in the patient's medical record using a rhythm strip before drug initiation and at least every 8 hours during treatment, as stated by the American Heart Association 3
Use the same ECG lead for QT measurements over time for consistency, as recommended by the American Heart Association 3
Consider using Fridericia's formula (QTcF = QT/∛RR) rather than Bazett's formula for heart rate correction, especially at higher heart rates, as suggested by the European Society of Cardiology 2, 4

If QTc reaches >500 ms or increases by >60 ms compared to baseline, treatment with metoclopramide should be discontinued or the dose reduced, as recommended by the European Society of Cardiology 2, 4
Correct any electrolyte abnormalities, particularly hypokalemia and hypomagnesemia, as stated by the American Heart Association 3, 4
Avoid concomitant use of multiple QT-prolonging medications, as recommended by the European Respiratory Society and the European Society of Cardiology 1, 2
Exercise particular caution in elderly patients and those with structural heart disease, as suggested by the European Society of Cardiology 2, 4

Metoclopramide with bedaquiline is a contraindicated combination, as stated by the European Respiratory Society 1
Metoclopramide with antiarrhythmics (quinidine, procainamide, disopyramide, sotalol, etc.) should be avoided, as recommended by the American Heart Association 3
Metoclopramide with other QT-prolonging drugs such as certain antipsychotics, antidepressants, and fluoroquinolones should be avoided, as suggested by the European Respiratory Society and the American Academy of Child and Adolescent Psychiatry 1, 5

Careful monitoring is especially important when metoclopramide is used in patients with cancer pain who may be receiving multiple medications, as stated by the National Comprehensive Cancer Network 6